No abstract

No abstract

No abstract

This study aims to assess the risk of colorectal stricture progressing to colorectal neoplasia (CRN) in patients with inflammatory bowel disease (IBD). The literature from PubMed, Embase, Web of Science, and Cochrane Library databases was searched from the date of databases’ creation to 5 November 2022. The Newcastle-Ottawa Scale was used to evaluate the quality of the included literature. Meta-analysis was conducted using the Stata 15 software and R 4.04 software. Two case-control studies and 12 cohort studies were eventually included. Colorectal stricture in patients with IBD increased the risk of progressing to CRN [odds ratio (OR): 1.52, 95% confidence interval (CI): 1.02–2.29, P = 0.042], but was irrelevant to the risk of progressing to ACRN (OR: 3.56, 95% CI 0.56–22.70, P = 0.180). The risk of CRN were further distinguished in patients with ulcerative colitis (UC) and Crohn’s disease (CD) Our findings showed that colorectal stricture may increase the risk of progressing to CRN in patients with UC (OR = 3.53, 95%CI 1.62–7.68, P = 0.001), but was irrelevant to the risk of progressing to CRN in patients with CD (OR = 1.09, 95% CI 0.54–2.21, P = 0.811). In conclusion, colorectal stricture in patients with IBD can be used as a risk factor for predicting CRN but cannot be used as a risk factor for predicting ACRN. Stricture is a risk factor for CRN in patients with UC but not in patients with CD. More prospective, multi-center studies with large samples are expected to confirm our findings.

Objective: To observe the effect of Jiawei Shengjiyuhong Ointment on wound repair of rat model after anal fistula surgery by regulating NF-κBp65 / IL-1β / VEGF signaling pathway. Methods : Sixty rats were divided into vaseline model group (n = 10), + Kangfuxin fluid control group (n = 10), modified Shengji Yuhong Ointment group (n = 10), and PDTC intervention model group (n = 30) (PDTC ++ Kangfuxinfluid group, PDTC + vaseline group, PDTC + modified Shengji Yuhong Ointment group, Ten rats in each group). The wound model of rats after anal fistula operation was established and intervened in different ways. The general situation and wound healing of rats in each group were recorded, and the wound healing rate of rats in each group was calculated. On the 3 th, 7 th and 14 th day, two rats in each group were randomly selected and sacrificed. The wound tissues of the same site were taken for Western blotting and immunohistochemistry to detect the protein and expression of NF-κBp65 in the wound tissues. The expression of IL-1β / VEGF was detected by elisa method. At the same time, HE staining was used to observe the histomorphology.Results : Compared with the model control group, the wound healing rate of the modified Shengji Yuhong ointment group and PDTC + modified Shengji Yuhong ointment group was the highest. HE staining results also confirmed that the wound healing degree of the modified Shengji Yuhong Ointment group and PDTC + modified Shengji Yuhong Ointment group was the best. The results of Western blotting and immunohistochemistry showed that the protein expression of NF-κBp65 in the wound tissue of rats was significantly inhibited in the Jiawei Shengji Yuhong Ointment group, PDTC + Jiawei Shengji Yuhong Ointment group and PDTC++ Kangfuxin fluid group and PDTC + Jiawei Shengji Yuhong Ointment had the best effect, and the difference was statistically significant compared with the control group and the model group (P < 0.05). The elisa method showed that the content of IL-1β in Jiawei Shengji Yuhong Ointment was lower than that in the control group and the model group (P < 0.05) at 3 day and 7 day after administration, and it showed a gradually decreasing trend. The content of IL-1β in PDTC + Jiawei Shengji Yuhong Ointment was the lowest. The content of VEGF in Jiawei Shengji Yuhong Ointment was higher than that in the control group and the model group (P < 0.05), and it showed a gradually increasing trend. The content of VEGF in PDTC + Jiawei Shengji Yuhong Ointment was the highest.Conclusion : Jiawei Shengji Yuhong Ointment can inhibit the expression of NF-κB p65 and IL-1β protein in NF-κB signaling pathway, up-regulate the expression of VEGF protein, promote epithelial cell proliferation, reduce inflammatory response, restore normal dermal fiber tissue, accelerate the recovery of wound tissue, and shorten the healing time.

Crohn's Disease (CD) is a chronic recurrent inflammatory bowel disease with unknown etiology, most common in the terminal ileum and adjacent colon. In the past 30 years, the global prevalence of CD has continued to rise. Although the etiology is unknown, studies have shown that it is closely related to geographical environment, microfold cell damage, intestinal flora changes, epithelial barrier damage, immune dysfunction and low. The main clinical manifestations of CD are abdominal pain, chronic diarrhea, fatigue, fever and weight loss. At present, 5-aminosalicylic acid, antibiotics, glucocorticoids, immunosuppressants and biological agents are mainly used for treatment, but the drug effect is limited and the effect is not good. Recent studies have shown that Mesenchymal Stem Cells (MSC) can down-regulate immune response and promote tissue healing, which has certain safety and effectiveness in the treatment of moderate and severe CD, and has broad application prospects, but also has certain limitations. This paper summarizes the application and efficacy of related therapies in CD, providing a reference for clinicians.